Your session is about to expire
← Back to Search
CBD for Cannabidiol
Study Summary
This trial is testing whether CBD can help treat psychosis in patients with schizophrenia, schizoaffective disorder, or bipolar disorder, compared to a placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 2 trial • 50 Patients • NCT01844687Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have had an allergic reaction to CBD or products that contain CBD in the past.You strongly prefer to use your left hand for most activities, according to a hand preference test.You have been diagnosed with alcohol or drug abuse or dependence within the past month or three months, as determined by the DSM-IV guidelines.You have thoughts of hurting others and have a plan to do so, making it necessary for you to receive inpatient care instead of outpatient care.You have a serious neurological condition or a severe medical condition that could affect how your brain functions.You have been diagnosed with schizophrenia, schizoaffective disorder, bipolar I disorder with psychotic features, or any other severe mental illness. Or, you are a healthy individual with no diagnosed severe mental illness.People of all races and ethnicities, including males and females, can participate.You have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder with psychotic features according to the DSM-IV criteria. Alternatively, you do not have any severe mental illness and are part of the control group.You are between 18 and 50 years old.
- Group 1: Patients with psychosis
- Group 2: Healthy controls
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the research include any participants aged 85 and above?
"According to the entry requirements for this medical trial, prospective participants must between 18 and 50 years of age."
What is the cap on the amount of participants in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this study - which was originally listed on December 15th 2021- is currently recruiting patients. 20 participants are needed from a single medical centre before the trial can begin."
To whom is eligibility for this clinical trial extended?
"This trial seeks 20 individuals aged 18 to 50 who have been diagnosed with cbd. In addition, they must match the diagnostic criteria in DSM-IV (SCID) for schizophrenia, schizoaffective disorder or bipolar I disorder with psychotic features; and be of any gender identity and ethnicity without a severe mental illness."
Have any further investigations been conducted regarding the efficacy of CBD?
"At this moment, 79 clinical trials involving cannabidiol are active. Of these studies, 16 have reached the third phase of their investigations. These medical examinations take place in cities across Brazil such as Ribeirao Preto and Sao Paulo with a total of 290 locations involved altogether."
Are there still slots available for study participants?
"According to data on clinicaltrials.gov, this medical research is actively seeking participants. The trial was initially published on December 15th 2021 and has since been updated as recent as August 1st 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger